Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Quince Therapeutics Inc

QNCX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$34.04

▲ +5.03%

Market Cap $33.29M · Vol 5.31K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$33.29M

Micro Cap

Div Yield

N/A

EPS Growth

+99.19%

YoY

RSI (14)

92.32

Momentum

Beta

1.36

vs Market

52W High

$908.00

96.25% below

52W Low

$15.10

125.43% above

Volume

5.31K

Avg 8.25K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

99.68%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Quince Therapeutics Inc (QNCX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does QNCX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+12.72%

+76.46%

+44.24%

-14.90%

YTD

-94.92%

-89.87%

-86.60%

-99.83%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-83,979,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-77.66% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+99.19%
Outstanding Shares	977.96K

Technical Indicators

50-Day SMA	$21.13
200-Day SMA	$197.97
RSI (14)	92.32
Beta	1.36
52-Week High	$908.00
52-Week Low	$15.10

Volume Today	5.31K
Avg Daily Volume (30D)	8.25K
Relative Volume	0.64x
Volatility (10D)	56.96
Volatility (30D)	66.84
Free Float	99.68%

Analyst Consensus

BUY

Current Price $34.04

Mean Target $82.75

52W Low$15.10 52W High$908.00

Current

Target

$15.10 $908.00

Current Analyst target

+143.10% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00BTK1DS9

ISINUS22053A2069

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateAug 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.